Additional Positive Findings For APOPTONE? (HE3235) In Preclinical Models Of Castration-Resistant Prostate Cancer
Oct 3rd 2008Drug InformationProstate
Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) today presented new findings that suggest APOPTONE? (HE3235) is inhibiting in preclinical models of castration-resistant prostate cancer, the ability of tumors to synthesize the hormones necessary for their survival, as well as significantly down regulating the androgen receptor.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
